CVRx CFO Jared Oasheim Steps Down for New Opportunities
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 09 2026
0mins
Source: Newsfilter
- Executive Transition: CVRx's CFO Jared Oasheim has announced his resignation to pursue other professional opportunities, with plans to remain as an advisor until February 2027, highlighting the company's commitment to leadership stability during this transition.
- Leadership Contributions: Since joining CVRx in 2015, Oasheim has played a pivotal role in the company's growth, successfully leading its initial public offering and establishing a finance organization that supports commercial growth, underscoring his significance in strategic implementation.
- Future Outlook: CVRx is initiating a search for a new CFO to succeed Oasheim, indicating the company's ongoing need for financial leadership as it continues to grow, which may impact future financial decisions and strategic direction.
- Industry Engagement: Oasheim and CEO Kevin Hykes are scheduled to present at the Goldman Sachs Global Healthcare Conference on June 10, 2026, showcasing the company's innovations in cardiovascular disease, which could enhance CVRx's visibility and influence in the industry.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CVRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CVRX
Wall Street analysts forecast CVRX stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 4.830
Low
11.00
Averages
12.50
High
14.00
Current: 4.830
Low
11.00
Averages
12.50
High
14.00
About CVRX
CVRx, Inc. is a commercial-stage medical device company. The Company is focused on developing, manufacturing and commercializing advanced neuromodulation solutions for patients with cardiovascular diseases. The Company's integrated platform technology, Barostim, is designed to leverage the power of the brain and nervous system to address the imbalance of the autonomic nervous system (ANS), which causes heart failure with reduced ejection fraction (HFrEF) and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy (BAT) by sending imperceptible and persistent electrical pulses to baroreceptors located in the wall of the carotid artery to signal the brain to modulate cardiovascular function. Barostim is a minimally invasive neuromodulation device that consists of two implantable components, an implantable pulse generator (IPG) and a stimulation lead, and is programmed by a wireless clinician-controlled programmer that communicates with the IPG.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
CVRx CFO Jared Oasheim Steps Down for New Opportunities
- Executive Change: CVRx's Chief Financial Officer Jared Oasheim has announced his resignation to pursue other opportunities, although he will remain as an advisor until February 2027 to ensure a smooth transition.
- Successor Search Initiated: The company has begun the search for Oasheim's successor but has not named an interim CFO or provided a timeline for the search, which may lead to uncertainty in management.
- Stock Price Reaction: Prior to the resignation announcement, CVRx's stock rose by 0.37% on Nasdaq, closing at $5.40, indicating a cautious optimism from the market regarding the company's future.
- Strategic Implications: The executive change could impact investor confidence, especially given the lack of a successor announcement, potentially affecting CVRx's financial stability and future strategic direction.
See More
CVRx CFO Jared Oasheim Steps Down for New Opportunities
- Executive Change: CVRx's Chief Financial Officer Jared Oasheim has announced his resignation to pursue other professional opportunities, although he will remain with the company until a successor is appointed to ensure stability during the transition.
- Advisory Role: Following his resignation, Oasheim will continue to serve as an advisor until February 2027, which helps maintain continuity in financial management as the company searches for a new CFO.
- Succession Search: CVRx is initiating a search for a new CFO, a move that could impact the company's financial strategy and future direction, especially ahead of upcoming earnings reports.
- Market Reaction: Following the announcement, CVRx's stock price fell by 1.30% in pre-market trading to $5.47, reflecting market caution regarding the executive change.
See More
CVRx CFO Jared Oasheim Steps Down for New Opportunities
- Executive Transition: CVRx's CFO Jared Oasheim has announced his resignation to pursue other professional opportunities, with plans to remain as an advisor until February 2027, highlighting the company's commitment to leadership stability during this transition.
- Leadership Contributions: Since joining CVRx in 2015, Oasheim has played a pivotal role in the company's growth, successfully leading its initial public offering and establishing a finance organization that supports commercial growth, underscoring his significance in strategic implementation.
- Future Outlook: CVRx is initiating a search for a new CFO to succeed Oasheim, indicating the company's ongoing need for financial leadership as it continues to grow, which may impact future financial decisions and strategic direction.
- Industry Engagement: Oasheim and CEO Kevin Hykes are scheduled to present at the Goldman Sachs Global Healthcare Conference on June 10, 2026, showcasing the company's innovations in cardiovascular disease, which could enhance CVRx's visibility and influence in the industry.
See More
CVRx Secures Medicare Coverage for Barostim Implant from Humana
- Medicare Coverage Announcement: Humana's decision to provide Medicare coverage for CVRx's Barostim cardiac implant starting May 1, 2026, represents a significant milestone as it is the first coverage policy for this heart failure device in the U.S., greatly enhancing CVRx's competitive position in the heart failure treatment market.
- Positive Market Reaction: Following Humana's announcement, CVRx shares rose approximately 4% in afternoon trading, reversing two consecutive days of declines, indicating increased investor confidence in the company's future prospects.
- Clinical Trial Inclusion: The coverage policy not only includes the FDA-approved indications but also extends to patients enrolled in CVRx's BENEFIT-HF trial, which is expected to broaden the device's applicability and drive market penetration in the heart failure sector.
- Optimistic Financial Outlook: CVRx projects revenue between $63 million and $67 million for 2026, and with the implementation of the coverage policy, the company anticipates further improvements in its financial performance and market position.
See More
CVRx Q1 2026 Earnings Call Highlights
- Significant Revenue Growth: CVRx reported total revenue of $14.8 million in Q1 2026, reflecting a $2.4 million increase or 20% year-over-year, indicating strong performance in the U.S. market that is expected to drive future business expansion.
- Improved Gross Margin: The gross margin for the first quarter rose to 87%, up from 84% a year ago, showcasing improvements in cost control and operational efficiency, which will enhance profitability moving forward.
- Ongoing Market Expansion: By the end of Q1, CVRx had increased its active implanting centers to 257 from 252 at the end of 2025, and expanded its sales territories from 53 to 56, demonstrating the company's continued efforts in market penetration.
- Optimistic Outlook: The company expects full-year revenue for 2026 to be between $63 million and $67 million, and despite facing reimbursement volatility, management remains optimistic about future growth, emphasizing sustained market demand and product innovation.
See More
CVRx Launches Landmark Heart Failure Trial
- Trial Launch: CVRx successfully enrolled the first patient at Avera Heart Hospital in South Dakota, marking the initiation of the BENEFIT-HF trial, which aims to recruit 2,500 patients and is set to be one of the largest therapeutic device trials in heart failure.
- Trial Scale: This multicenter, randomized controlled trial will be conducted at approximately 150 centers in the U.S. and Germany, designed to evaluate all-cause mortality and heart failure decompensation events, holding significant clinical implications.
- Therapeutic Potential: If successful, the trial could expand the indicated patient population for Barostim therapy by approximately three times, significantly broadening access to this treatment and enhancing its application in heart failure management.
- Industry Response: CVRx CEO Kevin Hykes noted that the early milestone reflects tremendous excitement in the healthcare community regarding the trial, emphasizing the importance of collaborating with leading physicians to develop meaningful clinical evidence, indicating the potential for long-term adoption of Barostim therapy.
See More
CVRx CFO Jared Oasheim Steps Down for New Opportunities
- Executive Change: CVRx's Chief Financial Officer Jared Oasheim has announced his resignation to pursue other opportunities, although he will remain as an advisor until February 2027 to ensure a smooth transition.
- Successor Search Initiated: The company has begun the search for Oasheim's successor but has not named an interim CFO or provided a timeline for the search, which may lead to uncertainty in management.
- Stock Price Reaction: Prior to the resignation announcement, CVRx's stock rose by 0.37% on Nasdaq, closing at $5.40, indicating a cautious optimism from the market regarding the company's future.
- Strategic Implications: The executive change could impact investor confidence, especially given the lack of a successor announcement, potentially affecting CVRx's financial stability and future strategic direction.
See More
CVRx CFO Jared Oasheim Steps Down for New Opportunities
- Executive Change: CVRx's Chief Financial Officer Jared Oasheim has announced his resignation to pursue other professional opportunities, although he will remain with the company until a successor is appointed to ensure stability during the transition.
- Advisory Role: Following his resignation, Oasheim will continue to serve as an advisor until February 2027, which helps maintain continuity in financial management as the company searches for a new CFO.
- Succession Search: CVRx is initiating a search for a new CFO, a move that could impact the company's financial strategy and future direction, especially ahead of upcoming earnings reports.
- Market Reaction: Following the announcement, CVRx's stock price fell by 1.30% in pre-market trading to $5.47, reflecting market caution regarding the executive change.
See More
CVRx CFO Jared Oasheim Steps Down for New Opportunities
- Executive Transition: CVRx's CFO Jared Oasheim has announced his resignation to pursue other professional opportunities, with plans to remain as an advisor until February 2027, highlighting the company's commitment to leadership stability during this transition.
- Leadership Contributions: Since joining CVRx in 2015, Oasheim has played a pivotal role in the company's growth, successfully leading its initial public offering and establishing a finance organization that supports commercial growth, underscoring his significance in strategic implementation.
- Future Outlook: CVRx is initiating a search for a new CFO to succeed Oasheim, indicating the company's ongoing need for financial leadership as it continues to grow, which may impact future financial decisions and strategic direction.
- Industry Engagement: Oasheim and CEO Kevin Hykes are scheduled to present at the Goldman Sachs Global Healthcare Conference on June 10, 2026, showcasing the company's innovations in cardiovascular disease, which could enhance CVRx's visibility and influence in the industry.
See More
CVRx Secures Medicare Coverage for Barostim Implant from Humana
- Medicare Coverage Announcement: Humana's decision to provide Medicare coverage for CVRx's Barostim cardiac implant starting May 1, 2026, represents a significant milestone as it is the first coverage policy for this heart failure device in the U.S., greatly enhancing CVRx's competitive position in the heart failure treatment market.
- Positive Market Reaction: Following Humana's announcement, CVRx shares rose approximately 4% in afternoon trading, reversing two consecutive days of declines, indicating increased investor confidence in the company's future prospects.
- Clinical Trial Inclusion: The coverage policy not only includes the FDA-approved indications but also extends to patients enrolled in CVRx's BENEFIT-HF trial, which is expected to broaden the device's applicability and drive market penetration in the heart failure sector.
- Optimistic Financial Outlook: CVRx projects revenue between $63 million and $67 million for 2026, and with the implementation of the coverage policy, the company anticipates further improvements in its financial performance and market position.
See More
CVRx Q1 2026 Earnings Call Highlights
- Significant Revenue Growth: CVRx reported total revenue of $14.8 million in Q1 2026, reflecting a $2.4 million increase or 20% year-over-year, indicating strong performance in the U.S. market that is expected to drive future business expansion.
- Improved Gross Margin: The gross margin for the first quarter rose to 87%, up from 84% a year ago, showcasing improvements in cost control and operational efficiency, which will enhance profitability moving forward.
- Ongoing Market Expansion: By the end of Q1, CVRx had increased its active implanting centers to 257 from 252 at the end of 2025, and expanded its sales territories from 53 to 56, demonstrating the company's continued efforts in market penetration.
- Optimistic Outlook: The company expects full-year revenue for 2026 to be between $63 million and $67 million, and despite facing reimbursement volatility, management remains optimistic about future growth, emphasizing sustained market demand and product innovation.
See More
CVRx Launches Landmark Heart Failure Trial
- Trial Launch: CVRx successfully enrolled the first patient at Avera Heart Hospital in South Dakota, marking the initiation of the BENEFIT-HF trial, which aims to recruit 2,500 patients and is set to be one of the largest therapeutic device trials in heart failure.
- Trial Scale: This multicenter, randomized controlled trial will be conducted at approximately 150 centers in the U.S. and Germany, designed to evaluate all-cause mortality and heart failure decompensation events, holding significant clinical implications.
- Therapeutic Potential: If successful, the trial could expand the indicated patient population for Barostim therapy by approximately three times, significantly broadening access to this treatment and enhancing its application in heart failure management.
- Industry Response: CVRx CEO Kevin Hykes noted that the early milestone reflects tremendous excitement in the healthcare community regarding the trial, emphasizing the importance of collaborating with leading physicians to develop meaningful clinical evidence, indicating the potential for long-term adoption of Barostim therapy.
See More
